The moral tollbooth: A method that makes use of the patent system to address ethical concerns in biotechnology

Lancet

Volumn 359, Issue 9325, 2002, Pages 2268-2270

  Gold, E Richard ^a   Caulfield, Timothy A ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; CANAVAN DISEASE; ECONOMIC ASPECT; EUROPE; HUMAN; MEDICAL ETHICS; MOLECULAR CLONING; MORALITY; NONHUMAN; PATENT; PRIORITY JOURNAL; PSEUDOXANTHOMA ELASTICUM; SHORT SURVEY; SOCIAL ASPECT;

EID: 0037193847     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)09298-X     Document Type: Note

References (24)

1. Intellectual property rights: Reforming the patent system
2. Rational limits on genomic patents
3. Commercialization of genetic research and public policy
4. Finding common cause in the patent debate
5. Moving the gene patent debate forward
6. Avoiding frankendrugs
7. Sovereignty and sharing
8. How can the developing world protect itself from biotech patent-holders
9. Genetic benefit sharing
10. Can patents deter innovation? The anticommons in biomedical research
11. Patenting human genetic material: Refocusing the debate
12. The commercialization of human genetics: A discussion of issues relevant to canadian consumers
13. Embryo research: British parliament approves new rules
14. Clones, controversy and criminal law: A comment on the proposal for legislation governing assisted human reproduction
15. The European biotech directive: Past as prologue
16. Families sue hospital scientist for control of Canavan gene
17. Tissue donors use their influence in deal over gene patent terms
18. Human-pig fusion patent bid set back